Clinical trial
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic…
NCT00024115 · National Cancer Institute (NCI), NIH · Withdrawn
Key facts
| NCT number | NCT00024115 |
|---|---|
| Title | BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
| Official title | Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | BL22 immunotoxin, antibody therapy, biological response modifier therapy, immunotoxin therapy |
| Enrollment | 0 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: